AUTH/2803/11/15 - Complainant v Alexion

Conference programme booklet

  • Case number
    AUTH/2803/11/15
  • Complaint received
    26 November 2015
  • Completed
    28 January 2016
  • Appeal hearing
    No appeal
  • Review
    February 2016
  • Applicable Code year
    2015
  • No breach Clause(s)
    2, 3.1, 3.2 and 9.1
  • Additional sanctions

Case Summary

A contactable complainant alleged that Alexion Pharma UK's entry in the programme booklet for a UK medical society meeting, held in Sheffield in November 2015, promoted an unlicensed medicine. 

The detailed response from Alexion is given below. 

​The Panel noted that the programme booklet included a list of the pharmaceutical companies and other organisations which had exhibited at or sponsored the event together with a paragraph about each. The paragraph about Alexion referred to the establishment of a premier global metabolic rare disease franchise with the development of two late-stage therapies, Strensiq for hypophosphatasia and Kanuma for lysosomal acid lipase deficiency. In the Panel's view some readers might consider that the wording implied that Strensiq and Kanuma were still in the late stages of development and that was not so. The Panel, however, noted Alexion's submission that the wording referred to the global development stage of the medicines and that both Strensiq and Kanuma had received a UK marketing authorization in August 2015 and therefore no pre licence promotion had taken place at the meeting in November 2015. The Panel thus ruled no breaches of the Code including no breach of Clause 2.